Open AccessSurvival Outcomes of Hypomethylating Agents Maintenance Therapy In New Diagnosed AML Patients: Real Experience Data
Author(s) -
Volkan Karakuş
Publication year - 2021
Publication title -
i̇stanbul kuzey klinikleri
Language(s) - English
Resource type - Journals
ISSN - 2148-4902
DOI - 10.14744/nci.2021.42800
Subject(s) - decitabine , medicine , azacitidine , hypomethylating agent , maintenance therapy , myeloid leukemia , oncology , chemotherapy , biochemistry , gene expression , dna methylation , gene , chemistry
Acute myeloid leukemia (AML) is a hematological malignancy that frequently affects elderly population. With introducing the hypomethylating agents (HMAs) in elderly AML treatment, survival rates and quality of life have improved. However, long-term management in elderly and frail patients is still a challenge. In the present study, we aimed to determine whether HMA maintenance therapy is required until disease progression in frail and elderly AML patients by examining with a real-life data.